Daiwa Securities Group’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.8M | Buy |
25,904
+540
| +2% | +$163K | 0.02% | 426 |
|
|
2026
Q1 | $8.39M | Sell |
25,364
-635
| -2% | -$216K | 0.02% | 358 |
|
|
2025
Q4 | $10.3M | Buy |
25,999
+10,503
| +68% | +$4.65M | 0.03% | 303 |
|
|
2025
Q3 | $7.07M | Buy |
15,496
+2,555
| +20% | +$1.04M | 0.02% | 371 |
|
|
2025
Q2 | $4.22M | Buy |
12,941
+35
| +0.3% | +$9.69K | 0.02% | 458 |
|
|
2025
Q1 | $3.48M | Buy |
12,906
+355
| +3% | +$91.2K | 0.01% | 470 |
|
|
2024
Q4 | $2.95M | Buy |
12,551
+479
| +4% | +$126K | 0.01% | 503 |
|
|
2024
Q3 | $3.32M | Buy |
12,072
+780
| +7% | +$203K | 0.02% | 461 |
|
|
2024
Q2 | $2.74M | Buy |
11,292
+371
| +3% | +$58.6K | 0.01% | 479 |
|
|
2024
Q1 | $1.63M | Buy |
10,921
+116
| +1% | +$19.4K | 0.01% | 605 |
|
|
2023
Q4 | $2.07M | Buy |
10,805
+400
| +4% | +$68.1K | 0.01% | 509 |
|
|
2023
Q3 | $1.84M | Sell |
10,405
-114
| -1% | -$21.8K | 0.01% | 517 |
|
|
2023
Q2 | $2M | Buy |
10,519
+71
| +0.7% | +$14.1K | 0.01% | 499 |
|
|
2023
Q1 | $2.09M | Buy |
10,448
+610
| +6% | +$128K | 0.01% | 484 |
|
|
2022
Q4 | $2.34M | Sell |
9,838
-1,430
| -13% | -$305K | 0.02% | 433 |
|
|
2022
Q3 | $2.25M | Buy |
11,268
+2,003
| +22% | +$382K | 0.02% | 427 |
|
|
2022
Q2 | $1.35M | Buy |
9,265
+312
| +3% | +$44.3K | 0.01% | 563 |
|
|
2022
Q1 | $1.46M | Buy |
8,953
+534
| +6% | +$81.4K | 0.01% | 590 |
|
|
2021
Q4 | $1.43M | Sell |
8,419
-76
| -0.9% | -$14.1K | 0.01% | 598 |
|
|
2021
Q3 | $1.6M | Buy |
8,495
+2,697
| +47% | +$506K | 0.01% | 552 |
|
|
2021
Q2 | $983K | Sell |
5,798
-2,015
| -26% | -$295K | 0.01% | 652 |
|
|
2021
Q1 | $1.1M | Buy |
7,813
+2,399
| +44% | +$361K | 0.01% | 583 |
|
|
2020
Q4 | $704K | Sell |
5,414
-436
| -7% | -$58.2K | 0.01% | 670 |
|
|
2020
Q3 | $852K | Buy |
5,850
+475
| +9% | +$67.5K | 0.01% | 549 |
|
|
2020
Q2 | $585K | Hold |
5,375
| – | – | 0.01% | 496 |
|
|
2020
Q1 | $585K | Hold |
5,375
| – | – | 0.01% | 607 |
|
|
2019
Q4 | $619K | Sell |
5,375
-79
| -1% | -$7.88K | 0.01% | 648 |
|
|
2019
Q3 | $439K | Buy |
5,454
+1,648
| +43% | +$130K | ﹤0.01% | 713 |
|
|
2019
Q2 | $276K | Hold |
3,806
| – | – | ﹤0.01% | 814 |
|
|
2019
Q1 | $356K | Buy |
3,806
+28
| +0.7% | +$2.34K | ﹤0.01% | 737 |
|
|
2018
Q4 | $275K | Buy |
3,778
+350
| +10% | +$26.9K | ﹤0.01% | 762 |
|
|
2018
Q3 | $300K | Hold |
3,428
| – | – | ﹤0.01% | 787 |
|
|
2018
Q2 | $338K | Hold |
3,428
| – | – | ﹤0.01% | 756 |
|
|
2018
Q1 | $408K | Buy |
3,428
+728
| +27% | +$93.9K | ﹤0.01% | 678 |
|
|
2017
Q4 | $343K | Buy |
+2,700
| New | +$339K | ﹤0.01% | 726 |
|
|
2016
Q4 | – | Sell |
-1,800
| Closed | -$122K | – | 1036 |
|
|
2016
Q3 | $122K | Hold |
1,800
| – | – | ﹤0.01% | 784 |
|
|
2016
Q2 | $100K | Hold |
1,800
| – | – | ﹤0.01% | 804 |
|
|
2016
Q1 | $113K | Buy |
1,800
+200
| +13% | +$13.3K | ﹤0.01% | 786 |
|
|
2015
Q4 | $151K | Hold |
1,600
| – | – | ﹤0.01% | 738 |
|
|
2015
Q3 | $129K | Buy |
1,600
+400
| +33% | +$44.4K | ﹤0.01% | 766 |
|
|
2015
Q2 | $144K | Buy |
+1,200
| New | +$143K | ﹤0.01% | 793 |
|
Other funds holding ALNY
Daiwa Securities Group's ALNY Position: Q2 2026 in Review
Daiwa Securities Group increased its Alnylam Pharmaceuticals (ALNY) stake by 2.1% in Q2 2026, buying an estimated $163K and bringing the position to 25,904 shares worth $7.8M. The position accounts for 0.02% of the portfolio, ranked #426.
Daiwa Securities Group first reported a position in ALNY in Q2 2015 and has held it in 41 quarters since. The position peaked at $10.3M in Q4 2025. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- Daiwa Securities Group held 25,904 shares of Alnylam Pharmaceuticals worth $7.8M as of Q2 2026.
- Daiwa Securities Group bought 540 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $163K.
- Alnylam Pharmaceuticals made up 0.02% of Daiwa Securities Group's portfolio in Q2 2026, its #426 holding.
- Daiwa Securities Group first reported a position in Alnylam Pharmaceuticals in Q2 2015 and has held it in 41 quarters since.
- Daiwa Securities Group's Alnylam Pharmaceuticals position peaked at $10.3M in Q4 2025.
- 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on Daiwa Securities Group's 13F filing for Q2 2026, filed 31 Jul 2026.